Marker Therapeutics, Inc.
MRKR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6,591 | $3,311 | $3,514 | $1,242 |
| % Growth | 99.1% | -5.8% | 183% | – |
| Cost of Goods Sold | $13,468 | $10,417 | $11,968 | $3,163 |
| Gross Profit | -$6,877 | -$7,106 | -$8,455 | -$1,921 |
| % Margin | -104.3% | -214.6% | -240.6% | -154.7% |
| R&D Expenses | $13,468 | $10,417 | $11,968 | $27,795 |
| G&A Expenses | $4,242 | $7,476 | $11,336 | $0 |
| SG&A Expenses | $4,242 | $7,476 | $11,336 | $9,762 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$13,468 | -$10,417 | -$11,968 | $0 |
| Operating Expenses | $4,242 | $7,476 | $11,336 | $37,557 |
| Operating Income | -$11,118 | -$14,581 | -$19,791 | -$39,478 |
| % Margin | -168.7% | -440.4% | -563.3% | -3,179.3% |
| Other Income/Exp. Net | $437 | $539 | $15 | -$2,401 |
| Pre-Tax Income | -$10,681 | -$14,042 | -$19,776 | -$41,879 |
| Tax Expense | $50 | $4 | $0 | $0 |
| Net Income | -$10,731 | -$8,237 | -$29,931 | -$41,879 |
| % Margin | -162.8% | -248.8% | -851.9% | -3,372.7% |
| EPS | -1.19 | -1.93 | -3.58 | -5.47 |
| % Growth | 38.3% | 46.1% | 34.6% | – |
| EPS Diluted | -1.19 | -1.93 | -3.58 | -5.47 |
| Weighted Avg Shares Out | 8,980 | 8,809 | 8,351 | 7,651 |
| Weighted Avg Shares Out Dil | 8,980 | 8,809 | 8,351 | 7,651 |
| Supplemental Information | – | – | – | – |
| Interest Income | $437 | $539 | $248 | $6 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $2,789 | $2,789 | $3,163 |
| EBITDA | -$11,118 | -$11,792 | -$17,002 | -$38,716 |
| % Margin | -168.7% | -356.1% | -483.9% | -3,118% |